International Journal of Hematology

, Volume 85, Issue 2, pp 116–120 | Cite as

Cutaneous langerhans cell sarcoma: a case report and review of the literature

  • Olga L. Bohn
  • Guillermo Ruiz-Argüelles
  • Leticia Navarro
  • Jesus Saldivar
  • Sergio Sanchez-Sosa
Case report

Abstract

Langerhans cell sarcoma (LCS) is a neoplastic proliferation of Langerhans cells that occurs in lymph nodes, liver, skin, spleen, lung, and bone. We report a case of LCS in a 47-year-old man with a 6-month history of scalp mass and cervical lym-phadenopathy. Clinical and pathologic data were available.A histologic examination demonstrated a proliferation of cells with malignant cytologic features. Because of its poorly differentiated morphologic features, hematologic and nonhematologic entities were ruled out by immunohistochemical screening with a broad panel of antibodies. Ultrastructural studies demonstrating Birbeck granules and consistent expression of CD1a, S-100 protein, and langerin by immunohistochemistry were helpful in identifying the Langerhans cell origin. Int J Hematol. 2007;85:116-120. doi: 10.1532/IJH97.NA0604

Key words

Langerhans cell sarcoma Langerhans histiocytic disorders Malignant Langerhans histiocytosis Langerhans cells Dendritic cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weiss LM, Grogan TM, Pileri SA, et al. Langerhans cell sarcoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:283.Google Scholar
  2. 2.
    Ben-Ezra J, Bailey A, Azumi N, et al. Malignant histiocytosis X: a distinct clinicopathologic entity. Cancer. 1991;68:1050–1060.PubMedCrossRefGoogle Scholar
  3. 3.
    Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1–29.PubMedCrossRefGoogle Scholar
  4. 4.
    Kawase T, Hamazaki M, Ogura M, et al. CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases. Int J Hematol. 2005;81:323–329.PubMedCrossRefGoogle Scholar
  5. 5.
    Wood C, Wood GS, Denaue DG, Oseroff A, Beckstead JH, Malin J. Malignant histiocytosis X: report of a rapidly fatal case in an elderly man. Cancer. 1984;54:347–352.PubMedCrossRefGoogle Scholar
  6. 6.
    Itoh H, Miyaguni H, Kataoka H, et al. Primary cutaneous Langerhans cell histiocytosis showing malignant phenotype in an elderly woman: report of a fatal case. J Cutan Pathol. 2001;28:371–378.PubMedCrossRefGoogle Scholar
  7. 7.
    Tani M, Ishii N, Kumagai M, Ban M, Sasase A, Mishima Y. Malignant Langerhans cell tumour. Br J Dermatol. 1992;126:398–403.PubMedCrossRefGoogle Scholar
  8. 8.
    Misery L, Godard W, Hamzeh H, et al. Malignant Langerhans cell tumor: a case with a favorable outcome associated with the absence of blood dendritic cell proliferation. J Am Acad Dermatol. 2003;49:527–529.PubMedCrossRefGoogle Scholar
  9. 9.
    Ferringer T, Banks PM, Metcalf JS. Langerhans cell sarcoma. Am J Dermatopathol. 2006;28:36–39.PubMedCrossRefGoogle Scholar
  10. 10.
    Jülg BD, Weidner S, Mayr D. Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. Virchows Arch. 2006;448:369–374.PubMedCrossRefGoogle Scholar
  11. 11.
    Lee JS, Ko GH, Kim HC, Jan IS, Jeon KN, Lee JH. Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. J Korean Med Sci. 2006;21:577–580.PubMedCrossRefGoogle Scholar
  12. 12.
    Wilson MS, Weiss LM, Gatter KC, Mason DY, Dorfman RF, Warnke RA. Malignant histiocytosis: a reassessment of cases previously reported in 1975 based on paraffin section immunophe- notyping studies. Cancer. 1990;66:530–536.PubMedCrossRefGoogle Scholar
  13. 13.
    Mongkonsritragoon W, Li CY, Phyliky R. True malignant histiocy- tosis. Mayo Clin Proc. 1998;73:520–528.PubMedCrossRefGoogle Scholar
  14. 14.
    Sato T, Terui T, Kogawa K, et al. A case of true malignant histiocy- tosis: identification of histiocytic origin with use of immunohisto- chemical and immunocytogenetic methods. Ann Hematol. 2002;81:285–288.PubMedCrossRefGoogle Scholar
  15. 15.
    Pillay K, Solomon R, Daubenton J, Sinclair-Smith CC. Interdigitat- ing dendritic cell sarcoma: a report of four paediatric cases and review of the literature. Histopathology. 2004;44:283–291.PubMedCrossRefGoogle Scholar
  16. 16.
    Chikwava K, Jaffe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol. 2004;7:607–614.PubMedCrossRefGoogle Scholar
  17. 17.
    Chu T, Jaffe R. The normal Langerhans cell and the LCH cell. Br J Cancer Suppl. 1994;23:S4-S10.PubMedGoogle Scholar
  18. 18.
    Valladeau J, Clair-Moninot V, Dezzuter-Dambuyant C, et al. Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J Immunol. 2002;168:782–792.PubMedGoogle Scholar
  19. 19.
    Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. Med Pediatr Oncol. 1997;29:157–166.PubMedCrossRefGoogle Scholar
  20. 20.
    Verdijk P, Dijkman R, Plasmeijer EI, et al. A lack of Birbeck granules in Langerhans cells is associated with a naturally occurring point mutation in the human langerin gene. J Invest Dermatol. 2005;124:714–717.PubMedCrossRefGoogle Scholar
  21. 21.
    Grogg KL, Lae ME, Kurtin PJ, et al. Clusterin expression distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms. Am J Surg Pathol. 2004;28:988–998.PubMedCrossRefGoogle Scholar
  22. 22.
    Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997;97:821–829.PubMedCrossRefGoogle Scholar
  23. 23.
    Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/natural killer-like T cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. 2001;19:2179–2188.PubMedGoogle Scholar
  24. 24.
    Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70–77.PubMedGoogle Scholar
  25. 25.
    Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemic and blastic NK cell lymphoma/leukemia. Leuk Res. 1999;23:615–624.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Olga L. Bohn
    • 1
  • Guillermo Ruiz-Argüelles
    • 2
  • Leticia Navarro
    • 1
  • Jesus Saldivar
    • 1
  • Sergio Sanchez-Sosa
    • 1
  1. 1.Department of PathologyUniversity Hospital UPAEPPueblaMexico
  2. 2.Department of HematologyClinica RuizPueblaMexico

Personalised recommendations